BCBSM/BCN Dual Header The Record Header Logo

The Record - Insurance Card with the BCBSM/BCN Cross and Shield logo that reads, Blue Cross Blue Shield, Blue Care Network of Michigan. Tagline: Confidence comes with every card. Image of Note boards with paper that has the letters RX on it accompanied by a stethoscope

Subscribe  |  The Record Archive  |  Contacts  |  bcbsm.com

November 2018

Professional

Training available for new medical and radiation oncology programs for URMBT members

Beginning Jan. 1, 2019, Blue Cross Blue Shield of Michigan will start two utilization management programs for oncology services given to UAW Retiree Medical Benefits Trust (URMBT) non-Medicare members. Blue Cross is partnering with AIM Specialty Health® for these programs, and we announced them in an October Record article.

In the coming months, there will be a series of webinars for providers and office staff to learn more about the programs and how to use the AIM ProviderPortalSM. We encourage you and your practice to participate even if you’re already familiar with AIM and the ProviderPortal through other health care plans or specialty programs.

There will be separate webinars for medical oncology and radiation oncology, and they will also be targeted toward clinical and non-clinical staff. The schedule is listed below.

Email providerinvitations@bcbsm.com to participate in one of these sessions and to obtain dial-in and webinar details.

Medical oncology
For non-clinical provider staff

Date

Time

Wednesday, Nov. 14, 2018

1-2 p.m. Eastern time (noon-1 p.m. Central time)

Thursday, Nov. 15, 2018

11 a.m.-noon Eastern time (10-11 a.m. Central time)

Tuesday, Dec. 11, 2018

10-11 a.m. Eastern time (9-10 a.m. Central time)

Tuesday, Jan. 22, 2019

10-11 a.m. Eastern time (9-10 a.m. Central time)

Wednesday, Jan. 23, 2019

Noon-1 p.m. Eastern time (11 a.m.-noon Central time)


For doctors and clinicians

Date

Time

Tuesday, Nov. 13, 2018

9-10 a.m. Eastern time (8-9 a.m. Central time)

Wednesday, Dec. 12, 2018

5-6 p.m. Eastern time (4-5 p.m. Central time)

Radiation oncology
For non-clinical provider staff

Date

Time

Tuesday, Nov. 13, 2018

12:30-1:30 p.m. Eastern time (11:30 a.m.-12:30 p.m. Central time)

Thursday, Nov. 15, 2018

9:30-10:30 a.m. Eastern time (8:30-9:30 a.m. Central time)

Tuesday, Dec. 11, 2018

1-2 p.m. Eastern time (noon-1 p.m. Central time)

Thursday, Dec. 13, 2018

10:30-11:30 a.m. Eastern time (9:30-10:30 a.m. Central time)  

Tuesday, Jan. 22, 2019

11:30 a.m.-12:30 p.m. Eastern time (10:30-11:30 a.m. Central time) 

Thursday, Jan. 24, 2019

1-2 p.m. Eastern time (noon-1 p.m. Central time)

For doctors and clinicians

Date

Time

Tuesday, Nov. 13, 2018

11 a.m.-noon Eastern time (10-11 a.m. Central time)

Wednesday, Dec. 12, 2018

1-2 p.m. Eastern time (noon-1 p.m. Central time) 

For more information about these programs, go to the AIM ProviderPortal** or call AIM at 1-800-728-8008. You can also visit bcbsm.com.

**Blue Cross Blue Shield of Michigan doesn’t own or control this website.


Reminder: Update your practice information, complete your attestation

It’s time for your quarterly review of your practice’s demographic information to make sure everything is up to date.

Individual practitioners:

  • Review all your practice locations.
  • Verify that CAQH ProView lists each location’s information correctly.
  • Don’t forget to check your address suite numbers and phone numbers, too.

Practice groups:

  • Verify that all practice locations are current, including suite numbers and phone numbers using the Provider Enrollment and Change Self-Service tool in Provider Secured Services.
  • Suppress locations and providers that don’t see patients for appointments. For example, emergency room physicians or administrative addresses shouldn’t display for members in our online directory.

More information and resources

  • CAQH ProView** — This site is helpful to both providers and practice managers.
  • Provider Secured Services This site provides steps to sign up for Provider Secured Services and get access to Provider Enrollment and Change Self-Service.
  • You can also call Provider Enrollment at 1-800-822-2761 to sign up for Provider Secured Services.

** Blue Cross Blue Shield of Michigan doesn't own or control this website.


Tell us how you answer the phone with our new feature in Provider Self-Service

How your office greets members by telephone is important — it helps them know they’ve reached the correct provider. As a result, the Centers for Medicare & Medicaid Services is now confirming how providers name their offices by phone through its annual data directory audit for health care plans.

To continue improving our member experience and stay compliant with CMS, we’ve added a new feature to the Provider Enrollment and Change Self-Service tool in Provider Secured Services. You can now add your office’s telephone greeting when adding or modifying your practice locations. We’ll display your office telephone greeting as your practice name in our online directory.

Why not update it now?
Log in to Provider Secured Services to access Provider Enrollment and Change Self-Service to refresh your practice location now and keep your online directory listing up to date.

If you have any questions, reach out to Provider Enrollment at 1-800-822-2761.


Remember to refer Blue Cross members to network providers

Providers affiliated with Blue Cross Blue Shield of Michigan and Blue Care Network have a contractual obligation to use network providers when referring our members for services. This includes referring members for toxicology and drug-of-abuse testing services, and applies to both Blue Cross and BCN commercial and Medicare Advantage members enrolled in the following plans:

  • Blue Cross PPO
  • Blue Cross Medicare Plus BlueSM PPO
  • BCN HMOSM
  • BCN AdvantageSM

A significant number of contracted providers refer members to out-of-network laboratories. This puts members at risk of having to pay higher costs. Since the tests are available at network labs, these additional costs are unnecessary. Follow the dictates of your provider agreement and the directions in our provider manuals, which instruct you to refer these members to network labs.

Our goal is to:

  • Give your patients convenient access to high-quality, cost-efficient toxicology testing services that meet their clinical needs.
  • Help our members avoid higher copayments and other out-of-pocket costs that may result from using out-of-network labs.

You can confirm which labs are in-network or out-of-network as follows:

Blue Cross PPO

  • For salaried employees covered through Ford, General Motors and the Michigan Public School Employees' Retirement System, call Quest Diagnostics™ at 1-866-697-8378.
  • For all other Blue Cross PPO members, use the Blue Cross online provider directory.

Blue Cross Medicare Plus Blue PPO
Call either of the following resources:

  • Joint Venture Hospital Laboratories — 1-800-445-4979
  • Quest Diagnostics — 1-866-697-8378

BCN HMO and BCN Advantage

  • Call Joint Venture Hospital Laboratories at 1-800-445-4979.

Contacting PARS
If you need more help locating a network lab or want to discuss specific lab testing needs, call one of the following Provider Automated Response System numbers during business hours:

Blue Cross PPO, BCN HMO or BCN Advantage

  • Professional providers — 1-800-344-8525
  • Facility providers — 1-800-249-5103

Blue Cross Medicare Care Blue PPO

  • 1-866-309-1719

After confirming member benefits using the automated system, you can speak to someone in Provider Inquiry to get help finding an in-network lab.


PCMH providers will receive board certification exceptions

Blue Cross Blue Shield of Michigan and Blue Care Network will continue to conduct annual board certification status reviews of family medicine, internal medicine and pediatric practitioners in our managed care networks.

However, effective Jan. 1, 2019, if board certification status has lapsed for a designated patient-centered medical home physician, Blue Cross will grant an exception and allow the practitioner to remain in our managed care networks. This exception doesn’t apply to new practitioner enrollments. We’ll continue to require that all practitioners have board certification upon initial enrollment for affiliation with us.

If board certification status has lapsed and the practitioner doesn’t have PCMH designation, he or she must complete his or her applicable specialty’s Maintenance of Certification requirements within a two-year time frame to remain in our managed care networks.


Continuity of Care in place for URMBT members in the medical or radiation oncology programs

Beginning Jan. 1, 2019, Blue Cross Blue Shield of Michigan will begin two new utilization management programs for oncology services delivered to UAW Retiree Medical Benefits Trust members. The programs require prior authorization for some outpatient medical and radiation oncology treatments through AIM Specialty Health®. We announced this in an October Record article.

Trust members who are in a current course of medical oncology or radiation oncology treatment (as described in the October article) as of Jan. 1, 2019, won’t need a prior authorization for six months. We’re doing this to ensure that these members don’t have an interruption in their care.

If treatment continues beyond six months or if a patient’s treatment path changes, a prior authorization will be required.

We’ll send additional communications directly to providers who are treating these members 30 days before the end of the six-month period to remind them that authorizations will be required.

For more information about these programs, go to the AIM ProviderPortal** or call AIM at 1-800-728-8008. You can also go to bcbsm.com.

**Blue Cross Blue Shield of Michigan doesn’t own or control this website.


New program for UAW Retiree Medical Benefits Trust members provides options for some diagnostic services

Beginning Jan. 1, 2019, Blue Cross Blue Shield of Michigan will offer a program for UAW Retiree Medical Benefits Trust members that allows them to choose from a list of health care providers for high-tech diagnostic imaging services.

The program, called Specialty Care Shopper, is offered in partnership with AIM Specialty Health®. With this program, members of the Trust who require diagnostic imaging services (e.g., MRI and CT scans) have an opportunity to choose from different health care providers. It allows the members to look for high-quality services while helping them keep their out-of-pocket costs as low as possible.

How will it work?
When a member needs an MRI or CT scan, his or her health care provider will prescribe one and obtain authorization for the service from AIM. AIM then reaches out to the member and offers him or her the choice of cost-effective options in the area (based on AIM’s online imaging provider registration tool, called OptiNet®).

If a member agrees to change his or her rendering provider, AIM will help do that.

How do I go register with AIM?
Go online to aimspecialtyhealth.com/goweb**. Then select BCBS Michigan from the dropdown menu. Fill out OptiNet tool information to be included as one of the rendering providers who will be suggested for Trust members.

The information requested includes:

  • A facility’s specifications
  • Technologist and physician qualifications
  • Accreditation
  • Equipment
  • Technical registration

AIM uses this information to determine how closely providers adhere to industry-recognized standards (such as those established by the American College of Radiology and the Intersocietal Accreditation Commission).

If you don’t register with AIM on the OptiNet registration tool, then your facility name won’t be included in the online directory and Trust members won’t be able to select you as part of the Shopper program.

It’s important to note, however, that Trust members can still receive services from providers who aren’t registered with AIM’s OptiNet program. The program is designed to help members make educated decisions about their care.

What happens to my information once I enter it?
Once you complete your registration, your responses are evaluated and given a score for each modality you perform. Your facility’s score and allowed payment amount will be shared with ordering physicians during the provider selection component of the prior authorization review.

What if I don’t register?
Then your facility name won’t be included in the online directory and Trust members won’t be able to select you as part of the Shopper program.

Note: Members can still receive services from providers who aren’t registered with AIM’s OptiNet program. This program is only designed to help members make educated decisions about their care.

I’ve already registered with AIM’s OptiNet tool. Do I have to re-register?
No. You don’t need to re-enter your information. But be sure to look at your information online to make sure it’s accurate.

**Blue Cross Blue Shield of Michigan doesn't own or control this website.


Coding corner: Major depressive disorder

Major depressive disorder, also known as clinical depression, is a common but serious mood disorder. It affects how one feels, thinks and behaves. A person having trouble doing activities nearly every day for at least two weeks may be suffering from this disorder. Always document signs and symptoms of MDD in the patient’s medical record to support the diagnosis. Include details of the most recent episode.

Examples of symptoms of an MDD episode:

  • Depressed or irritable mood
  • Decreased interest or pleasure
  • Change in activity
  • Fatigue or loss of energy
  • Diminished concentration, memory or ability to make decisions
  • Guilt or sense of worthlessness
  • Significant change in weight or appetite
  • Change in sleep patterns
  • Restlessness, inability to sit still
  • Aches or pains, headaches, cramps or digestive problems without a clear physical cause and that don’t subside with treatment
  • Thoughts of death, self-harm or suicide

MDD is assigned to the following ICD-10-CM categories:

  • F32 — Major depressive disorder, single episode
  • F33 — Major depressive disorder, recurrent

Categories F32 and F33 include fourth characters, and sometimes fifth characters, to capture information about the severity of the MDD. The severity can be defined as:

  • Mild: The patient experiences at least five of the symptoms needed for a diagnosis, which also pose a mild overall functional impairment.
  • Moderate: The patient experiences at least seven to eight symptoms, or the symptoms pose a moderate overall functional impairment.
  • Severe without psychotic features: The patient experiences most or all the symptoms, or the symptoms pose a severe functional impairment, but the patient presents without any psychotic features.
  • Severe with psychotic features: The patient experiences most or all the symptoms, or the symptoms pose a severe functional impairment and the patient presents with psychotic features.
  • In full remission: The patient previously had two or more episodes but has been free from symptoms for at least two months.
  • In partial remission: Some symptoms may still be present, but the full criteria are no longer met, or there are no longer any significant symptoms of an episode, but the patient hasn’t been in remission for two months or longer.

If information isn’t present in the medical record that identifies the severity of the disorder, the ICD-10-CM classification includes “unspecified” diagnosis codes. Unspecified codes are used when the information in the medical record is insufficient to assign a more specific code.

Caution should be taken to only code the medical condition that’s stated in the medical record, even when documentation of the clinical requirements for a different level of severity is noted in the medical record. For example, if “depression” is documented but the medical record also states, “Exhibits sadness and is withdrawing from friends,” only the depression can be coded.

The diagnosis is what is coded. Additional clinical documentation would be considered supporting documentation for the depression. Providers should clearly state the level of severity of the depression and correlate this with supporting documentation, such as current prescribed medications, a Patient Health Questionnaire-9, or PHQ-9, or another standardized assessment.

ICD-10-CM code subcategory choices for MDD:

ICD 10

Description

F32.0

Major depressive disorder, single episode, mild

F32.1

Major depressive disorder, single episode, moderate

F32.2

Major depressive disorder, single episode, severe without psychotic features

F32.3

Major depressive disorder, single episode, severe with psychotic features

F32.4

Major depressive disorder, single episode, in partial remission

F32.5

Major depressive disorder, single episode, in full remission

F32.9

Major depressive disorder, single episode, unspecified

F33.0

Major depressive disorder, recurrent, mild

F33.1

Major depressive disorder, recurrent, moderate

F33.2

Major depressive disorder, recurrent, severe without psychotic features

F33.3

Major depressive disorder, recurrent, severe with psychotic features

F33.4

Major depressive disorder, recurrent, in remission

F33.9

Major depressive disorder, recurrent, unspecified

Note: Medical record documentation that simply states “depression” and has no further supporting documentation will index to subcategory F32.9, Major depressive disorder, single episode, unspecified per the ICD-10-CM Alphabetic Index.

2018 Updates ICD- 10-CM Official Guidelines for Coding and Reporting
(Updates are in bold)

Chapter 5: Mental, Behavioral and Neurodevelopmental Disorders (F01 – F99)

b. Mental and behavioral disorders due to psychoactive substance use

1) In Remission
Selection of codes for “in remission” for categories F10-F19, Mental and behavioral disorders due to psychoactive substance use (categories F10-F19 with -11, -.21) requires the provider’s clinical judgment. The appropriate codes for “in remission” are assigned only on the basis of provider documentation (as defined in the Official Guidelines for Coding and Reporting), unless otherwise instructed by the classification.

Mild substance use disorders in early or sustained remission are classified to the appropriate codes for substance abuse in remission, and moderate or severe substance use disorders in early or sustained remission are classified to the appropriate codes for substance dependence in remission.

3) Psychoactive Substance Use Disorders
As with all other diagnoses, codes for psychoactive substance use disorders (F10.9-, F11.9-, F12.9-, F13.9-, F14.9-, F15.9-, F16.9-) should only be assigned based on provider documentation and when they meet the definition of a reportable diagnosis (see Section III, Reporting Additional Diagnoses). Use these codes only when the psychoactive substance use is associated with a physical, mental or behavioral disorder, and such a relationship is documented by the provider.


Reminder: FEP made changes to care admissions request for skilled nursing facility

On April 30, 2018, all post-acute care admissions, including skilled nursing facilities, were routed to the Precertification Utilization Management team. Federal Employee Program® members must sign a consent for case management to use their benefit for a skilled nursing facility. All clinical information along with the member’s signed consent for case management can be faxed to 1-866-411-2573 for precertification review.

Note: If an FEP member has Medicare Part B, and also has Medicare Part B services on the claim, then that claim must be submitted to Medicare for processing before FEP can process the claim.  

FEP benefit coverage

SNF benefit

Basic Option

No benefit for inpatient skilled nursing facility care.

Standard Option with primary Medicare Part A

Limited to coverage of the first through 30th day for each benefit period as defined by Medicare. Medicare covers days 1-20 in full.

For days 21-30, Medicare covers the stay except for the copayment, which FEP covers.

There’s no FEP benefits beyond 30 days. Members can’t use a Flexible Option Benefit to cover SNF additional days.

FEP considers medical necessity as being met when Medicare Part A has made a payment for the stay.

Standard Option with no primary Medicare Part A**

**Member doesn’t have Medicare Part A or has Secondary Medicare Part A

FEP covers SNF admissions for a maximum of 30 days annually. The benefit is also available to overseas members.

Requires precertification for medical necessity for the SNF setting.

Before admission, the member must provide signed consent for case management services enrollment and participate in case management throughout his or her SNF stay.

If you have benefit questions, contact FEP Customer Service at 1-800-482-3600. If you have facility precertification questions, contact precertification at 1-800-572-3413. If you have questions about case management services, call 1-800-325-6278.


Reminder: FEP programs help members manage a chronic condition

The Blue Cross Blue Shield Federal Employee Program® offers initiatives to encourage members with a reported diagnosis of diabetes or hypertension to make healthier choices to reduce the progression of complications related to diabetes or heart disease.

To manage high blood pressure

The Hypertension Management Program provides contract holders and their spouses who are 18 and older with a free blood pressure monitor through CVS Caremark®. Members are automatically enrolled in the program following three qualifications.

  • They complete the FEP Blue Health Assessment.
  • Members report a diagnosis of high blood pressure.
  • At least one medical claim has been processed during the past 12 months with a diagnosis of hypertension.

To manage diabetes

The Diabetes Management Incentive Program is designed to encourage members to achieve and maintain control of their blood sugar and help manage or slow the progression of complications related to diabetes. Through this program, eligible members can earn a maximum of $100 toward a health account to be used for most qualified medical expenses.

The Diabetes Meter Program allows members with diabetes to receive, at no cost, one glucometer kit each calendar year. Members will still need to obtain a prescription for test strips and lancets for the new meter from their doctor.

FEP members

Members with hypertension or diabetes are encouraged to participate in these programs. They are voluntary, free and confidential. The self-monitoring tools provided by these programs support members’ efforts to manage their chronic conditions.

For more information about these and other health care programs offered by the Blue Cross Blue Shield Federal Employee Program, members should contact FEP Customer Service at 1-800-482-3600 or visit fepblue.org.


Scoring hypopnea in adults: Which standard is acceptable?

What’s hypopnea?

Hypopnea, a partial blockage of the airway, is a feature of a condition called obstructive sleep apnea hypopnea syndrome. Hypopnea is a type of sleep apnea. It’s characterized by slow or shallow breathing while apnea means periods of no breathing.

There’s been some confusion among health care providers about what criteria Blue Cross Blue Shield of Michigan will accept for diagnostic purposes when scoring hypopnea in adults.

There are two standards used in scoring hypopnea. The American Academy of Sleep Medicine** recommends a 3 percent or greater oxygen desaturation from the pre-event baseline or the event associated with an arousal, while the Centers for Medicare & Medicaid Services requires a 4 percent or greater oxygen desaturation.

Keep in mind that Blue Cross will accept either standard when scoring hypopnea.

To read more about Blue Cross’ sleep apnea policy, see the policy titled Continuing Coverage of CPAP Machines and Supplies for the Treatment of Obstructive Sleep Apnea. To access our medical policies, follow these steps:

  • From the web-DENIS homepage, click on BCBSM Provider Publications and Resources.
  • To search for a policy by procedure code, click on Benefit policy for a code.
  • If you don’t have the code, click on Medical Policy and Precert/Pre-Auth Router.

**Blue Cross Blue Shield of Michigan doesn’t own or control this website.


Procedure code D0190 not a covered dental or medical benefit

As a reminder, procedure code D0190 isn’t a covered dental or medical benefit. This dental code indicates screening (including state or federally mandated screening) used to determine an individual's need to be seen by a dentist for diagnosis.

Professional providers who provide screening for this purpose shouldn’t bill procedure code D0190. This service is considered an integral part of a routine evaluation and management service and isn’t separately reimbursable.


Commercial Medical Drug Prior Authorization Program adding Onpattro

Beginning Dec. 1, 2018, Onpattro™ will be added to the Blue Cross Blue Shield of Michigan commercial Medical Drug Prior Authorization Program.

Drug name

HCPCS code

Onpattro™ (patisiran)

J3490

The list below shows all medications currently in the Medical Drug Prior Authorization Program.

Drug name

HCPCS code

Drug name

HCPCS code

Drug name

HCPCS code

Actemraz®

J3262

Gammagard®

J1569

Privigen®

J1459

Acthar® gel

J0800

Gammaked®

J1561

Probuphine®

J3490 / J3590

Adagen®

J2504

Gammaplex®

J1557

Prolastin®-C

J0256

Aldurazyme®

J1931

Gamunex®

J1561

Prolia®

J0897

Aralast NP™

J0256

Glassia™

J0257

Radicava™

J3490 / J3590

Aveed®

J3145

Hizentra®

J1559

Remicade®

J1745

Benlysta®

J0490

HyQvia®

J1575

Renflexis™

Q5104

Berinert®

J0597

Ilaris®

J0638

Ruconest®

J0596

Bivigam™

J1556

Ilumya®

J3590

Signifor®LAR

J2502

Botox®

J0585

Immune globulin NOS

J1599

Simponi Aria®

J1602

Brineura™

J3490 / J3590

Inflectra™

Q5103

Soliris®

J1300

Carimune® NF

J1566

Kalbitor®

J1290

Spinraza™

J2326

Cerezyme®

J1786

Kanuma™

J2840

Stelara®

J3357

Cimzia®

J0717

Krystexxa®

J2509

Stelara IV®

J3358 

Cinqair®

J2786

Kymriah™

Q2040

Synagis®

90378

Cinryze®

J0598

Lucentis®

J2778

Testopel®

S0189

Crysvita®

J3490 / J3590

Lumizyme®

J0221

Trogarzo™

J3590

Cuvitru®

J1599

Luxturna™

J3490 / J3590

Vimizim™

J1322

Dysport®

J0586

Makena®

J1725

Vpriv®

J3385

Elaprase®

J1743

Mepsevii™

J3490 / J3590

Xeomin®

J0588

Elelyso™

J3060

Myobloc®

J0587

Xgeva®

J0897

Entyvio™

J3380

Myozyme®

J0220

Xiaflex®

J0775

Exondys 51™

J1428

Naglazyme®

J1458

Xolair®

J2357

Fabrazyme®

J0180

Nplate®

J2796

Yescarta™

Q2041

Fasenra™

J3490 / J3590

Nucala®

J2182

Zemaira®

J0256

Firazyr®

J1744

Octagam®

J1568

Zilretta®

Q9993

Flebogamma® DIF

J1572

Orencia®

J0129

Zinplava™

J0565

Keep in mind that prior authorization is a clinical review approval only — not a guarantee of payment.

Our office accepts medical drug prior authorization requests by one of the following methods:

Fax

Mail

Phone

1-877-325-5979

Blue Cross Blue Shield of Michigan Specialty Pharmacy Program
P.O. Box 2320
Detroit, MI 48231-2320

1-800-437-3803

You can find prior authorization forms for all physician-administered medications on web-DENIS. When logged in, follow these steps:

  1. Click on BCBSM Provider Publications and Resources.
  2. Click on Commercial Pharmacy Prior Authorization and Step Therapy forms.
  3. Click on Under Other Resources, then select Forms.
  4. Click on Physician administered medications.

Our standard processing time to review requests is 15 days. We’ll review urgent requests within 72 hours.

Note: The prior authorization requirement doesn’t apply to Federal Employee Program® members.

Blue Cross reserves the right to change the prior authorization list at any time.


Facility

Training available for new medical and radiation oncology programs for URMBT members

Beginning Jan. 1, 2019, Blue Cross Blue Shield of Michigan will start two utilization management programs for oncology services given to UAW Retiree Medical Benefits Trust (URMBT) non-Medicare members. Blue Cross is partnering with AIM Specialty Health® for these programs, and we announced them in an October Record article.

In the coming months, there will be a series of webinars for providers and office staff to learn more about the programs and how to use the AIM ProviderPortalSM. We encourage you and your practice to participate even if you’re already familiar with AIM and the ProviderPortal through other health care plans or specialty programs.

There will be separate webinars for medical oncology and radiation oncology, and they will also be targeted toward clinical and non-clinical staff. The schedule is listed below.

Email providerinvitations@bcbsm.com to participate in one of these sessions and to obtain dial-in and webinar details.

Medical oncology
For non-clinical provider staff

Date

Time

Wednesday, Nov. 14, 2018

1-2 p.m. Eastern time (noon-1 p.m. Central time)

Thursday, Nov. 15, 2018

11 a.m.-noon Eastern time (10-11 a.m. Central time)

Tuesday, Dec. 11, 2018

10-11 a.m. Eastern time (9-10 a.m. Central time)

Tuesday, Jan. 22, 2019

10-11 a.m. Eastern time (9-10 a.m. Central time)

Wednesday, Jan. 23, 2019

Noon-1 p.m. Eastern time (11 a.m.-noon Central time)


For doctors and clinicians

Date

Time

Tuesday, Nov. 13, 2018

9-10 a.m. Eastern time (8-9 a.m. Central time)

Wednesday, Dec. 12, 2018

5-6 p.m. Eastern time (4-5 p.m. Central time)

Radiation oncology
For non-clinical provider staff

Date

Time

Tuesday, Nov. 13, 2018

12:30-1:30 p.m. Eastern time (11:30 a.m.-12:30 p.m. Central time)

Thursday, Nov. 15, 2018

9:30-10:30 a.m. Eastern time (8:30-9:30 a.m. Central time)

Tuesday, Dec. 11, 2018

1-2 p.m. Eastern time (noon-1 p.m. Central time)

Thursday, Dec. 13, 2018

10:30-11:30 a.m. Eastern time (9:30-10:30 a.m. Central time)  

Tuesday, Jan. 22, 2019

11:30 a.m.-12:30 p.m. Eastern time (10:30-11:30 a.m. Central time) 

Thursday, Jan. 24, 2019

1-2 p.m. Eastern time (noon-1 p.m. Central time)

For doctors and clinicians

Date

Time

Tuesday, Nov. 13, 2018

11 a.m.-noon Eastern time (10-11 a.m. Central time)

Wednesday, Dec. 12, 2018

1-2 p.m. Eastern time (noon-1 p.m. Central time) 

For more information about these programs, go to the AIM ProviderPortal** or call AIM at 1-800-728-8008. You can also visit bcbsm.com.

**Blue Cross Blue Shield of Michigan doesn’t own or control this website.


Remember to refer Blue Cross members to network providers

Providers affiliated with Blue Cross Blue Shield of Michigan and Blue Care Network have a contractual obligation to use network providers when referring our members for services. This includes referring members for toxicology and drug-of-abuse testing services, and applies to both Blue Cross and BCN commercial and Medicare Advantage members enrolled in the following plans:

  • Blue Cross PPO
  • Blue Cross Medicare Plus BlueSM PPO
  • BCN HMOSM
  • BCN AdvantageSM

A significant number of contracted providers refer members to out-of-network laboratories. This puts members at risk of having to pay higher costs. Since the tests are available at network labs, these additional costs are unnecessary. Follow the dictates of your provider agreement and the directions in our provider manuals, which instruct you to refer these members to network labs.

Our goal is to:

  • Give your patients convenient access to high-quality, cost-efficient toxicology testing services that meet their clinical needs.
  • Help our members avoid higher copayments and other out-of-pocket costs that may result from using out-of-network labs.

You can confirm which labs are in-network or out-of-network as follows:

Blue Cross PPO

  • For salaried employees covered through Ford, General Motors and the Michigan Public School Employees' Retirement System, call Quest Diagnostics™ at 1-866-697-8378.
  • For all other Blue Cross PPO members, use the Blue Cross online provider directory.

Blue Cross Medicare Plus Blue PPO
Call either of the following resources:

  • Joint Venture Hospital Laboratories — 1-800-445-4979
  • Quest Diagnostics — 1-866-697-8378

BCN HMO and BCN Advantage

  • Call Joint Venture Hospital Laboratories at 1-800-445-4979.

Contacting PARS
If you need more help locating a network lab or want to discuss specific lab testing needs, call one of the following Provider Automated Response System numbers during business hours:

Blue Cross PPO, BCN HMO or BCN Advantage

  • Professional providers — 1-800-344-8525
  • Facility providers — 1-800-249-5103

Blue Cross Medicare Care Blue PPO

  • 1-866-309-1719

After confirming member benefits using the automated system, you can speak to someone in Provider Inquiry to get help finding an in-network lab.


Continuity of Care in place for URMBT members in the medical or radiation oncology programs

Beginning Jan. 1, 2019, Blue Cross Blue Shield of Michigan will begin two new utilization management programs for oncology services delivered to UAW Retiree Medical Benefits Trust members. The programs require prior authorization for some outpatient medical and radiation oncology treatments through AIM Specialty Health®. We announced this in an October Record article.

Trust members who are in a current course of medical oncology or radiation oncology treatment (as described in the October article) as of Jan. 1, 2019, won’t need a prior authorization for six months. We’re doing this to ensure that these members don’t have an interruption in their care.

If treatment continues beyond six months or if a patient’s treatment path changes, a prior authorization will be required.

We’ll send additional communications directly to providers who are treating these members 30 days before the end of the six-month period to remind them that authorizations will be required.

For more information about these programs, go to the AIM ProviderPortal** or call AIM at 1-800-728-8008. You can also go to bcbsm.com.

**Blue Cross Blue Shield of Michigan doesn’t own or control this website.


Reminder: FEP made changes to care admissions request for skilled nursing facility

On April 30, 2018, all post-acute care admissions, including skilled nursing facilities, were routed to the Precertification Utilization Management team. Federal Employee Program® members must sign a consent for case management to use their benefit for a skilled nursing facility. All clinical information along with the member’s signed consent for case management can be faxed to 1-866-411-2573 for precertification review.

Note: If an FEP member has Medicare Part B, and also has Medicare Part B services on the claim, then that claim must be submitted to Medicare for processing before FEP can process the claim.  

FEP benefit coverage

SNF benefit

Basic Option

No benefit for inpatient skilled nursing facility care.

Standard Option with primary Medicare Part A

Limited to coverage of the first through 30th day for each benefit period as defined by Medicare. Medicare covers days 1-20 in full.

For days 21-30, Medicare covers the stay except for the copayment, which FEP covers.

There’s no FEP benefits beyond 30 days. Members can’t use a Flexible Option Benefit to cover SNF additional days.

FEP considers medical necessity as being met when Medicare Part A has made a payment for the stay.

Standard Option with no primary Medicare Part A**

**Member doesn’t have Medicare Part A or has Secondary Medicare Part A

FEP covers SNF admissions for a maximum of 30 days annually. The benefit is also available to overseas members.

Requires precertification for medical necessity for the SNF setting.

Before admission, the member must provide signed consent for case management services enrollment and participate in case management throughout his or her SNF stay.

If you have benefit questions, contact FEP Customer Service at 1-800-482-3600. If you have facility precertification questions, contact precertification at 1-800-572-3413. If you have questions about case management services, call 1-800-325-6278.


Scoring hypopnea in adults: Which standard is acceptable?

What’s hypopnea?

Hypopnea, a partial blockage of the airway, is a feature of a condition called obstructive sleep apnea hypopnea syndrome. Hypopnea is a type of sleep apnea. It’s characterized by slow or shallow breathing while apnea means periods of no breathing.

There’s been some confusion among health care providers about what criteria Blue Cross Blue Shield of Michigan will accept for diagnostic purposes when scoring hypopnea in adults.

There are two standards used in scoring hypopnea. The American Academy of Sleep Medicine** recommends a 3 percent or greater oxygen desaturation from the pre-event baseline or the event associated with an arousal, while the Centers for Medicare & Medicaid Services requires a 4 percent or greater oxygen desaturation.

Keep in mind that Blue Cross will accept either standard when scoring hypopnea.

To read more about Blue Cross’ sleep apnea policy, see the policy titled Continuing Coverage of CPAP Machines and Supplies for the Treatment of Obstructive Sleep Apnea. To access our medical policies, follow these steps:

  • From the web-DENIS homepage, click on BCBSM Provider Publications and Resources.
  • To search for a policy by procedure code, click on Benefit policy for a code.
  • If you don’t have the code, click on Medical Policy and Precert/Pre-Auth Router.

**Blue Cross Blue Shield of Michigan doesn’t own or control this website.


Update or review your demographic information twice a year

Our Provider Enrollment and Data Management team mails your demographic data to you twice a year. When you receive them:

  • Review and confirm the accuracy of your demographic information.
  • Respond to each mailing to keep your demographic data up to date.

If you don’t respond with information updates or confirm that your current information is correct, it won’t appear in our online directory.

Help our members find and reach you
Blue Cross Blue Shield of Michigan and Blue Care Network members rely on the online provider directory for accurate, up-to-date provider information. If there are any changes or updates to your demographics, send them to us via:

  • Mail
    Provider Enrollment — Attestation
    20500 Civic Center Drive
    Southfield, MI 48076-4115
    H200–PDA
  • Fax
    1-844-216-4941
  • Email
    providerdataintegrity@bcbsm.com

If you have questions or need support making updates, visit bcbsm.com or call Provider Enrollment at 1–800–822–2761.


Pharmacy

AllianceRx Walgreens Prime specialty pharmacy program starts Jan. 1

AllianceRx Walgreens Prime has become the exclusive provider of specialty pharmacy services for some Blue Cross Blue Shield of Michigan and Blue Care Network commercial (non-Medicare) members. Blue Cross has notified the affected members about this change.

To ensure there’s no interruption in therapy, you’ll need to write a new prescription for your affected patients before Jan. 1, 2019, if:

  • They have Blue Cross or BCN insurance coverage that requires them to get specialty medications from AllianceRx Walgreens Prime.
  • They’re currently using a pharmacy other than a Walgreens retail location or AllianceRx Walgreens Prime (formerly Walgreens Specialty Pharmacy) for a specialty medication.

Take no action for patients with remaining refills for prescriptions currently filled at a Walgreens retail location or AllianceRx Walgreens Prime.

About AllianceRx Walgreens Prime
AllianceRx Walgreens Prime will help patients with complex health conditions get convenient access to medications you prescribe that:

  • Need injections
  • Need to be taken on a strict schedule
  • Have special storage needs

AllianceRx Walgreens Prime will:

  • Reduce the demands on your time.
  • Help simplify the referral process.
  • Handle insurance verification, prior authorization and financial assistance coordination.
  • Provide a team of pharmacists, nurses and patient care coordinators to help ensure your patients get the specialty pharmacy care they deserve.

In addition, patient care coordinators will regularly contact your patients to offer helpful information. They’ll also provide guidance that encourages medication compliance, and they’ll:

  • Help your patients better understand their complex health conditions.
  • Work with Blue Cross to coordinate and verify pharmacy benefits, as necessary.
  • Assist your patients when they need new or existing prescriptions filled, and schedule refills.
  • Encourage your patients to take their medications exactly as prescribed.
  • Help your patients manage medication side effects.
  • Evaluate responses to prescribed medication therapies.
  • Call prescribers when necessary.
  • Offer access to pharmacists by telephone 24/7.
  • Deliver specialty medications to the most clinically appropriate sites that meet your patients’ needs (such as your office, a clinic, treatment center or a patient’s home or workplace).

For more information, visit alliancerxwp.com/hcp.**

**Blue Cross Blue Shield of Michigan doesn’t own or control this website.


Commercial Medical Drug Prior Authorization Program adding Onpattro

Beginning Dec. 1, 2018, Onpattro™ will be added to the Blue Cross Blue Shield of Michigan commercial Medical Drug Prior Authorization Program.

Drug name

HCPCS code

Onpattro™ (patisiran)

J3490

The list below shows all medications currently in the Medical Drug Prior Authorization Program.

Drug name

HCPCS code

Drug name

HCPCS code

Drug name

HCPCS code

Actemraz®

J3262

Gammagard®

J1569

Privigen®

J1459

Acthar® gel

J0800

Gammaked®

J1561

Probuphine®

J3490 / J3590

Adagen®

J2504

Gammaplex®

J1557

Prolastin®-C

J0256

Aldurazyme®

J1931

Gamunex®

J1561

Prolia®

J0897

Aralast NP™

J0256

Glassia™

J0257

Radicava™

J3490 / J3590

Aveed®

J3145

Hizentra®

J1559

Remicade®

J1745

Benlysta®

J0490

HyQvia®

J1575

Renflexis™

Q5104

Berinert®

J0597

Ilaris®

J0638

Ruconest®

J0596

Bivigam™

J1556

Ilumya®

J3590

Signifor®LAR

J2502

Botox®

J0585

Immune globulin NOS

J1599

Simponi Aria®

J1602

Brineura™

J3490 / J3590

Inflectra™

Q5103

Soliris®

J1300

Carimune® NF

J1566

Kalbitor®

J1290

Spinraza™

J2326

Cerezyme®

J1786

Kanuma™

J2840

Stelara®

J3357

Cimzia®

J0717

Krystexxa®

J2509

Stelara IV®

J3358 

Cinqair®

J2786

Kymriah™

Q2040

Synagis®

90378

Cinryze®

J0598

Lucentis®

J2778

Testopel®

S0189

Crysvita®

J3490 / J3590

Lumizyme®

J0221

Trogarzo™

J3590

Cuvitru®

J1599

Luxturna™

J3490 / J3590

Vimizim™

J1322

Dysport®

J0586

Makena®

J1725

Vpriv®

J3385

Elaprase®

J1743

Mepsevii™

J3490 / J3590

Xeomin®

J0588

Elelyso™

J3060

Myobloc®

J0587

Xgeva®

J0897

Entyvio™

J3380

Myozyme®

J0220

Xiaflex®

J0775

Exondys 51™

J1428

Naglazyme®

J1458

Xolair®

J2357

Fabrazyme®

J0180

Nplate®

J2796

Yescarta™

Q2041

Fasenra™

J3490 / J3590

Nucala®

J2182

Zemaira®

J0256

Firazyr®

J1744

Octagam®

J1568

Zilretta®

Q9993

Flebogamma® DIF

J1572

Orencia®

J0129

Zinplava™

J0565

Keep in mind that prior authorization is a clinical review approval only — not a guarantee of payment.

Our office accepts medical drug prior authorization requests by one of the following methods:

Fax

Mail

Phone

1-877-325-5979

Blue Cross Blue Shield of Michigan Specialty Pharmacy Program
P.O. Box 2320
Detroit, MI 48231-2320

1-800-437-3803

You can find prior authorization forms for all physician-administered medications on web-DENIS. When logged in, follow these steps:

  1. Click on BCBSM Provider Publications and Resources.
  2. Click on Commercial Pharmacy Prior Authorization and Step Therapy forms.
  3. Click on Under Other Resources, then select Forms.
  4. Click on Physician administered medications.

Our standard processing time to review requests is 15 days. We’ll review urgent requests within 72 hours.

Note: The prior authorization requirement doesn’t apply to Federal Employee Program® members.

Blue Cross reserves the right to change the prior authorization list at any time.


All Providers

We’ve made enhancements to PARS

We’re expanding our self-service offerings to help meet your business needs. This includes a change to the Provider Automated Response System, known as PARS.

Effective Nov. 1, 2018, providers will have the ability to receive benefits and eligibility information for infusion therapy when selecting the following practices:

  • General practice
  • DME
  • Pediatrics
  • Other services

Simply say “infusion” to receive benefits and eligibility information. After hearing the benefits, you’ll have the opportunity to speak to a live servicing agent.

Using PARS is:

  • Quick — Inquiry is answered within a few minutes.
  • Convenient — It’s available 24 hours a day, seven days a week.
  • Personalized — Caller controls the information he or she wants to hear or skip.
  • Accurate — Receipt of a fax or email provides documentation of the information received on a given day.

PARS provides information for:

  • Blue Cross Blue Shield of Michigan and Blue Care Network commercial
  • Medicare Advantage
  • Federal Employee Program®
  • Professional, facility, vision and hearing

When calling with questions about the determination of a claim, our Customer Service representatives will encourage you to use PARS to retrieve your information. They’ll help you navigate through the system and find what you’re looking for.


Reminder: How to bill when Blue Cross is secondary payer

When billing Blue Cross Blue Shield of Michigan as a secondary payer, providers are required to accept our allowed amount for covered services. This policy is part of our professional participation agreement with providers.

If you have questions, contact Provider Inquiry.


We’ve added a Documentation Guidelines section to Benefit Explainer

To make it easier for you to find information about medical criteria, payment policies and procedure code updates, we’ve added a Documentation Guidelines tab to Benefit Explainer.

To find the Documentation Guidelines tab in Benefit Explainer:

  • Log in to Provider Secured Services.
  • Select web-DENIS.
  • Click on BCBSM Provider Publications and Resources.
  • Click on Benefit Policy for a Code.
  • Select Medical/Payment Policy or the BPR tab.
  • Click on Topic to select and enter desired search criteria.
  • Select Finish, then click on Search.
  • Medical Payment Policy Report or BPR Report displays.
  • Click on Additional Information.
  • Select Documentation Guidelines to view the information.

The information found under the Documentation Guidelines tab will still be available in The Record billing chart and web-DENIS alerts.

Here’s what the new tab looks like through the Medical/Payment Policy Report tab:

1

Here’s what the new tab looks like through the BPR tab:

2


HCPCS and CPT update: New codes added

The Centers for Medicare & Medicaid Services has added several new HCPCS and CPT codes. The codes, effective dates and Blue Cross Blue Shield of Michigan’s coverage decisions are below.

HCPCS codes

Outpatient Prospective Payment System — Injection

Code

Change

Coverage comments

Effective date

C9033

Added

Covered for facility only

Oct. 1, 2018

C9034

Added

Covered for facility only

Oct. 1, 2018

C9750

Deleted

Not covered

Oct. 30, 2018

Medicine/professional — Evaluation and management

Code

Change

Coverage comments

Effective date

G9978

Added

Not covered

Oct. 1, 2018

G9979

Added

Not covered

Oct. 1, 2018

G9980

Added

Not covered

Oct. 1, 2018

G9981

Added

Not covered

Oct. 1, 2018

G9982

Added

Not covered

Oct. 1, 2018

G9983

Added

Not covered

Oct. 1, 2018

G9984

Added

Not covered

Oct. 1, 2018

G9985

Added

Not covered

Oct. 1, 2018

G9986

Added

Not covered

Oct. 1, 2018

G9987

Added

Not covered

Oct. 1, 2018

Medicine Supplementary — Injections

Code

Change

Coverage comments

Effective date

Q5109

Added

Covered

Oct. 1, 2018

Q5110

Added

Covered

Oct. 1, 2018

Medicine/professional — Miscellaneous/data gathering codes

Code

Change

Coverage comments

Effective date

G9978

Deleted

Deleted

Jan. 1, 2018

G9979

Deleted

Deleted

Jan. 1, 2018

CPT codes
Pathology and Laboratory — Proprietary laboratory analysis codes

Code

Change

Coverage comments

Effective date

0020U

Deleted

Deleted

Sept. 30, 2018

0028U

Deleted

Deleted

Sept. 30, 2018

0062U

Added

Not covered

Oct. 1, 2018

0063U

Added

Not covered

Oct. 1, 2018

0064U

Added

Covered

Oct. 1, 2018

0065U

Added

Covered

Oct. 1, 2018

0066U

Added

Not covered

Oct. 1, 2018

0067U

Added

Not covered

Oct. 1, 2018

0068U

Added

Covered

Oct. 1, 2018

0069U

Added

Not covered

Oct. 1, 2018

0070U

Added

Not covered

Oct. 1, 2018

0071U

Added

Not covered

Oct. 1, 2018

0072U

Added

Not covered

Oct. 1, 2018

0073U

Added

Not covered

Oct. 1, 2018

0074U

Added

Not covered

Oct. 1, 2018

0075U

Added

Not covered

Oct. 1, 2018

0076U

Added

Not covered

Oct. 1, 2018

0077U

Added

Covered

Oct. 1, 2018

0078U

Added

Not covered

Oct. 1, 2018

0079U

Added

Not covered

Oct. 1, 2018

None of the information included in this article is intended to be legal advice and, as such, it remains the provider’s responsibility to ensure that all coding and documentation are done in accordance with all applicable state and federal laws and regulations


Battling the opioid epidemic: A roundup of news and information

Michigan opioid overdose deaths hit new record
The Detroit Free Press** reported Oct. 4 that overdose deaths from opioids reached a record high in Michigan last year, according to a new report released by the Michigan Department of Health and Human Services. The report says that 1,941 of the last year's 2,729 overdose deaths were opioid-related, an increase of 9 percent over 2016. This represents a slowing of the year-over-year increase in opioid-related deaths. Between 2015 and 2016, opioid overdose deaths jumped 35 percent.

Senate passes bills to address opioid epidemic
The Senate passed a sweeping package of bills Sept. 17 aimed at addressing the nation’s deadly opioid epidemic, The Washington Post** reported. Last year, President Trump and Congress had vowed a federal government response to a crisis that affects millions of Americans and is responsible for the deaths of close to 50,000 last year. The package of 70 Senate bills costs $8.4 billion and creates, expands and renews programs across multiple agencies.

Opioids before joint replacement tied to worse recovery
Prolonged use of opioid painkillers before total knee or hip replacement may greatly increase a patient’s risk of repeat surgery and hospitalization, according to a new study in the Journal of Bone & Joint Surgery, HealthDay® News** reported. Hospital readmission rates in the knee replacement group were 1.4 percent higher among those who used painkillers for more than 60 days and 2.2 percent higher within the hip replacement group.

CDC releases study on opioid use disorder in labor and delivery
The Centers for Disease Control and Prevention recently released the first multi-state analysis of trends** in opioid use disorder in labor and delivery. The analysis indicated that the number of pregnant women with OUD at labor and delivery more than quadrupled from 1999 through 2014, with significant increases in every one of the 28 states with available data. For more information, see the CDC’s graphic,** which highlights strategies to address opioid use disorder and improve maternal and infant health.

Blue plans working together to improve addiction treatment
Blue Cross Blue Shield of Michigan is working with doctors and other experts nationwide to make sure our members have access to the most effective addiction treatment centers to get the care they need. A new Blue Cross Blue Shield Association program, which will include a new designation for effective treatment programs, builds upon the existing Blue Distinction® programs that identify the high-quality doctors and hospitals. For more information, see the MI Blues Perspectives blog.

Study: Nearly 30 percent of opioid prescriptions lack clear clinical explanation
A study published in the Annals of Internal Medicine found that 28.5 percent of opioid prescriptions written in the U.S. between 2006 and 2015 lacked a documented clinical reason, USA Today** reported. The findings, based on analysis of data from the National Ambulatory Medical Care Survey, showed 66 percent of opioid prescriptions were for noncancer pain while 5 percent were intended to treat cancer-related pain.

GDAHC recognizes Michigan OPEN for health care leadership
The Greater Detroit Area Health Council recognized Michigan Opioid Prescribing and Engagement Network with the Eagle Award for Visionary Leadership. The award recognizes the contributions of an organization in Southeast Michigan that has made steady progress in advancing health care quality, access or cost. Michigan OPEN, along with other leaders in health care, will be honored Nov. 8 at the 2018 Salute to Healthcare celebration. For information about Michigan OPEN initiatives, visit Michigan-open.org.**

**Blue Cross Blue Shield of Michigan doesn’t own or control this website.


MESSA is launching new product, effective Jan. 1

The Michigan Education Special Services Association is launching a new product called Essentials by MESSA, effective Jan. 1, 2019. This product is an addition to existing MESSA plans.

Essentials by MESSA offers premiums and deductibles that are lower than some other MESSA products, made possible by reducing and eliminating some benefits that members have said aren’t crucial to their health care needs. As always, providers should refer to web-DENIS for benefits before rendering services.


Billing chart: Blues highlight medical, benefit policy changes

You’ll find the latest information about procedure codes and Blue Cross Blue Shield of Michigan billing guidelines in the following chart.

This billing chart is organized numerically by procedure code. Newly approved procedures will appear under the New Payable Procedures heading. Procedures for which we have changed a billing guideline or added a new payable group will appear under Updates to Payable Procedures. Procedures for which we are clarifying our guidelines will appear under Policy Clarifications. New procedures that are not covered will appear under Experimental Procedures.

You will also see that descriptions for the codes are no longer included. This is a result of recent negotiations with the AMA on use of the codes.

We will publish information about new BCBS groups or changes to group benefits under the Group Benefit Changes heading.

For more detailed descriptions of the BCBSM policies for these procedures, please check under the Medical/Payment Policy tab in Explainer on web-DENIS. To access this online information:

  • Log in to web-DENIS.
  • Click on BCBSM Provider Publications & Resources.
  • Click on Benefit Policy for a Code.
  • Click on Topic.
  • Under Topic Criteria, click on the drop-down arrow next to Choose Identifier Type and then click on HCPCS Code.
  • Enter the procedure code.
  • Click on Finish.
  • Click on Search.
Code* BCBSM changes to:
Basic Benefit and Medical Policy, Group
Variations Payment Policy, Guidelines
NEW PAYABLE PROCEDURES

77061, 77062, 77063

Basic benefit and medical policy

PPO Radiology Management Program

The following provider specialties are payable for procedure codes 77061, 77062 and 77063 under the PPO Radiology Management Program, effective March 1, 2018:

  • 01 — General Practice
  • 03 — Allergy
  • 08 — Family practice
  • 09 — Gynecology
  • 10 — Gastroenterology
  • 11 — Internal medicine
  • 15 — Obstetrics
  • 16 — OB-gynecology
  • 76 — Preventive medicine
  • AF — Infectious disease
  • UC — Urgent care provider
  • WC — Family practice-sports medicine
  • WJ — Pediatric sports and fitness medicine

J3590 

Basic benefit and medical policy

Crysvita (burosumab-twza)

Crysvita (burosumab-twza) is considered established, effective April 17, 2018.

Crysvita (burosumab-twza) is covered when all the following criteria are met:

  • The patient is 18 to 65 years old.
  • It’s prescribed by endocrinologist.
  • Treatment is for the underlying cause of X-linked hypophosphatemia (XLH).
  • Serum Pi < 2.5 mg/dL.
  • Measurable bone/joint pain (≥4 BPI-Q3 worst pain).
  • There was a trial and failure of preferred products.

Quantity limits align with FDA-recommended dosing. The initial authorization period is six months.

Renewal criteria:
Authorization will be reviewed at least annually to assess improvement. The renewal authorization period is one year.

FDA-approved indication and diagnosis:

  • Crysvita is indicated for the treatment of X-linked hypophosphatemia in adult and pediatric patients ages 1 and older.

 Dosing:

  • Pediatric: Starting dose regimen is 0.8 mg/kg of body weight rounded to the nearest 10 mg, administered every two weeks. The minimum starting dose is 10 mg, up to a maximum dose of 90 mg. Dose may be increased up to approximately 2 mg/kg (maximum 90 mg), administered every two weeks to achieve normal serum phosphorus.
  • Adult: Dose regimen is 1 mg/kg body weight rounded to the nearest 10 mg up to a maximum dose of 90 mg administered every four weeks.

It’s administered by subcutaneous injection by a health care provider.

How supplied:

  • Injection: 10 mg/mL, 20 mg/mL, or 30 mg/mL in a single-dose vial

Crysvita (burosumab-twza) isn’t a benefit for URMBT.

Prior authorization is required.

NDCs: 69794-0102-01, 69794-0203-01, 69794-0304-01.

J3590

Basic benefit and medical policy

Ilumya (tildrakizumab-asmn)

Ilumya (tildrakizumab-asmn) is considered established, effective March 20, 2018.

Ilumya (tildrakizumab-asmn) is covered with chart notes to support a diagnosis of moderate to severe plaque psoriasis and when all the below criteria are met:

  • The patient is age 18 or older.
  • The prescribing physician is a dermatologist.
  • Treatment with a minimum of three months of topical steroids was ineffective.
  • Treatment with phototherapy or photochemotherapy was ineffective, contraindicated or not tolerated.
  • Treatment with at least one generic oral systemic agent for plaque psoriasis was ineffective or not tolerated, unless contraindicated. Examples of systemic agents include, but are not limited to, cyclosporine, methotrexate and acitretin.
  • Trial and failure of preferred drugs as required by Blue Cross Blue Shield of Michigan.
  • Patients may not use Ilumya in combination with other biologics (e.g., Enbrel®, Stelara®).

Quantity limit: FDA-approved dosing.

Authorization period: Approve for one year.

Renewal criteria: Improvement in plaque psoriasis symptoms.

FDA-approved indication and diagnosis:

  • Treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Dosing and administration:

  • Administer subcutaneously at a dose of 100 mg at weeks 0, 4, and every 12 weeks thereafter.

How supplied:

  • Injection: 100 mg/mL solution in a single-dose prefilled syringe

Ilumya (tildrakizumab-asmn) isn’t a benefit for URMBT.

Prior authorization is required.

NDC: 00006-4241-00.

J3590

Basic benefit and medical policy

Retacrit (epoetin alfa-epbx)

Effective May 15, 2018, Retacrit (epoetin alfa-epbx) was covered for the FDA-approved indications below.

Retacrit (epoetin alfa-epbx) is a biosimilar to Epogen/Procrit (epoetin alfa). Retacrit (epoetin alfa-epbx) is an erythropoiesis-stimulating agent indicated for the following:

  • Treatment of anemia due to:
    • Chronic kidney disease, or CKD, in patients on dialysis and not on dialysis
    • Zidovudine in patients with HIV infection
    • The effects of concomitant myelosuppressive chemotherapy. Upon initiation, there’s a minimum of two additional months of planned chemotherapy.
  • Reduction of allogeneic RBC transfusions in patients undergoing elective, noncardiac and nonvascular surgery.

Retacrit (epoetin alfa-epbx) hasn’t been shown to improve quality of life, fatigue or patient well-being.

Retacrit (epoetin alfa-epbx) isn’t indicated for use:

  • In patients with cancer who are receiving hormonal agents, biologic products or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy
  • In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure
  • In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion
  • In patients scheduled for surgery who are willing to donate autologous blood
  • In patients undergoing cardiac or vascular surgery
  • As a substitute for red blood cell transfusions in patients who require immediate correction of anemia.

Evaluate iron status before and during treatment and maintain iron repletion. Correct or exclude other causes of anemia before initiating treatment.

Patients with CKD:
Initial dose: 50 to 100 units/kg three times weekly (adults) and 50 units/kg three times weekly (pediatric patients). Individualize maintenance dose. Intravenous route recommended for patients on hemodialysis.

Patients on zidovudine due to HIV infection: 100 units/kg three times weekly.

Patients with cancer undergoing chemotherapy: 40,000 units weekly or 150 units/kg three times weekly (adults); 600 units/kg intravenously weekly (pediatric patients > 5 years).

Surgery patients: 300 units/kg per day daily for 15 days or 600 units/kg weekly.

Pharmacy doesn’t require preauthorization of this drug.

Retacrit (epoetin alfa-epbx) isn’t a benefit for URMBT.

NDCs

 

 

00069 1308 01

59353 0002 01

00069 1307 01

00069 1308 10

59353 0002 10

00069 1307 10

59353 0010 01

00069 1306 01

59353 0004 01

59353 0010 10

00069 1306 10

59353 0004 10

00069 1305 01

59353 0003 01

00069 1309 01

00069 1305 10

59353 0003 10

00069 1309 04

S0353, S0354

Basic benefit and medical policy

Medical Oncology AIM program for URMBT
non-Medicare only

Effective Jan. 1, 2019, these codes will be payable under the Medical Oncology AIM program for URMBT non-Medicare only.

UPDATES TO PAYABLE PROCEDURES

81210

Basic benefit and medical policy

BRAF mutation in selecting melanoma/glioma patients for targeted therapy

Testing for BRAF V600 variants in tumor tissue of patients with unresectable or metastatic melanoma is established to select patients for treatment with FDA-approved BRAF or MEK inhibitors.

Testing for BRAF V600 variants in tumor tissue of patients with resected stage III melanoma is established to select patients for treatment with FDA-approved BRAF or MEK inhibitors.

Testing for BRAF V600 variants for all other patients with melanoma is considered experimental.

Testing for BRAF V600 variants in patients with glioma to select patients for targeted treatment is considered experimental.

This policy is effective Nov. 1, 2018.

Refer to the pharmacy policies (Vemurafenib, Trametinib, Cobimetinib) for patient selection.

81401, 81405, 81406

Basic benefit and medical policy

Genetic testing for heterozygous familial hypercholesterolemia

The effectiveness and clinical utility of genetic testing to confirm a diagnosis or future risk of familial hypercholesterolemia, or FH, have been established. It may be considered a useful diagnostic option when indicated, effective Nov. 1, 2018.

Payment policy
Note: These procedures require manual review.

Inclusions:
Genetic testing to confirm a diagnosis of familial hypercholesterolemia when all the following are met:

  • A definitive diagnosis is required as an eligibility criterion for specialty medications
  • The individual is in an uncertain category according to clinical criteria (personal and family history, physical exam, lipid levels).
    • All the following apply:
      • FH is suspected and evaluated against standardized diagnostic criteria.
      • Criteria for a definite diagnosis are not met.
  • Alternative treatment considerations are in place for individuals who have an uncertain diagnosis of FH and a negative genetic test.

Genetic testing to determine future risk of familial hypercholesterolemia when all the following are met:

  • A pathogenic variant is present in a biological parent.
  • General lipid screening is not recommended based on age or other factors.

Exclusions:

  • Genetic testing to confirm diagnosis of FH for all other situations not listed above
  • Genetic testing of adults who are close relatives of individuals with FH to determine future risk, other than the above

91110

Not covered: 91111, 0355T, 91299

Basic benefit and medical policy

Wireless capsule endoscopy
Wireless capsule endoscopy has been proven to be safe and effective. It’s a useful therapeutic option for patients meeting patient selection criteria.

The peer reviewed medical literature is insufficient to determine the effectiveness of the patency capsule (e.g., Given AGILE™). Therefore, it’s considered experimental, including in the evaluation of the patency of the GI tract before wireless capsule endoscopy.

This policy has been updated, effective Nov. 1, 2018.

Inclusions:

  • Initial diagnosis in patients with suspected Crohn’s disease without evidence of disease on conventional diagnostic tests, such as small-bowel follow-through, or SBFT, and upper and lower endoscopy
  • In patients with an established diagnosis of Crohn’s disease, when there are unexpected changes in the course of disease or response to treatment, suggesting the initial diagnosis may be incorrect and re-examination may be indicated
  • Evaluation for the extent of involvement or management of known Crohn’s disease
  • Suspected small bowel bleeding, as evidenced by prior inconclusive upper and lower gastrointestinal endoscopic studies
  • For surveillance of the small bowel in patients with hereditary GI polyposis syndromes, including familial adenomatous polyposis and Peutz-Jeghers syndrome

Exclusions:

  • Evaluation for the extent of involvement or management of known ulcerative colitis.
  • Evaluation of the esophagus in patients with gastroesophageal reflux or other esophageal pathologies.
  • Evaluation of other gastrointestinal diseases not presenting with GI bleeding, including, but not limited to, celiac sprue, irritable bowel syndrome, Lynch syndrome, portal hypertensive enteropathy, small bowel neoplasm and unexplained chronic abdominal pain
  • Evaluation of the colon, including, but not limited to, detection of colonic polyps or colon cancer
  • Initial evaluation of patients with acute upper GI bleeding
  • Use of wireless capsule for routine colorectal cancer screening, confirmation of lesions or pathology normally within the reach of upper or lower endoscopes
  • In patients with known or suspected gastrointestinal obstruction, strictures or fistulas

The patency capsule (e.g., Given AGILE™) is considered experimental, including in the evaluation of the patency of the GI tract before wireless capsule endoscopy.

96446, 96549**

**Use unlisted procedure when infusion is performed using a temporary catheter or performed intraoperatively.

Note: Other codes related to the cytoreduction would also be billed, depending on the organs and tissues removed during the surgical debulking.

Basic benefit and medical policy

Cytoreductive surgery and perioperative intraperitoneal chemotherapy for select intra-abdominal and pelvic malignancies

The safety and effectiveness of hyperthermic intraperitoneal chemotherapy, or HIPEC, when used in combination with cytoreductive surgery have been established. It may be considered a useful therapeutic option for patients meeting patient selection criteria.

Inclusionary criteria have been updated, effective Nov. 1, 2018.

Inclusions:
The patient must meet all the following criteria:

  • A diagnosis of pseudomyxoma peritonei, diffuse malignant peritoneal mesotheliomas or ovarian cancer confirmed by the treating physician.
  • The patient must be able to tolerate the extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
  • Peritoneal disease must be potentially completely resectable or significantly reduced.
  • There must be no metastases to other organs or to the retroperitoneal space.

Exclusions:

  • A diagnosis of peritoneal carcinomatosis from colorectal cancer, gastric cancer or endometrial cancer
  • Goblet cell tumors of the appendix
  • All other indications

E0650-E0652, E0655, E0660, E0665-
E0669, E0671-E0673

Not covered: E0656, E0657, E0676, E1399

Basic benefit and medical policy

Pneumatic compression pumps (Flexitouch™ System) for lymphedema

Pneumatic compression pumps for upper and lower extremities are established for the treatment of lymphedema in individuals who have failed conservative therapies.

Pneumatic compression pumps for the trunk/chest or head/neck are experimental.

This policy is effective Nov. 1, 2018.

Inclusions:
Single-compartment or multichamber nonprogrammable lymphedema pumps applied to the limb are established for the treatment of lymphedema that has failed to respond to conservative measures, such as elevation of the limb and use of compression garments.

Single-compartment or multichamber programmable lymphedema pumps applied to the limb are established for the treatment of lymphedema when all of the following criteria are met:

  1. The individual is otherwise eligible for nonprogrammable pumps.
  2. There is documentation that the individual has unique characteristics that prevent satisfactory pneumatic compression with single-compartment or multichamber nonprogrammable lymphedema pumps (e.g., significant scarring).

Exclusions:
Single-compartment or multichamber lymphedema pumps applied to the limb are considered experimental in all situations not mentioned above.

The use of lymphedema pumps to treat trunk/chest lymphedema in patients is considered experimental.

The use of lymphedema pumps to treat head/neck lymphedema in patients is considered experimental.

J9999

Basic benefit and medical policy

Darzalex (daratumumab)

Darzalex (daratumumab) is established for its new indication in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant, effective May 7, 2018.

POLICY CLARIFICATIONS

33418, 33419, 0345T

Not covered: 0483T, 0484T

Basic benefit and medical policy

Transcatheter mitral valve repair

The safety and effectiveness of transcatheter mitral valve repair have been established and may be considered a useful option when performed with an FDA-approved transcatheter valve device and specified criteria are met.

The safety and efficacy of transcatheter implantable mitral valve annulus reshaping devices for the treatment of mitral valve regurgitation are under clinical trial evaluation. Therefore, this service is experimental.

Exclusionary criteria have been updated, effective Nov. 1, 2018.

Inclusions:
Transcatheter mitral valve repair with an FDA-approved mitral valve repair system (i.e. Mitraclip®) is indicated when all the criteria are met:

  • Significant symptomatic mitral regurgitation (MR ≥ 3+) due to primary abnormality of the mitral apparatus (degenerative MR)
  • Patients who have been determined to be at prohibitive risk for open mitral valve surgery by a heart team, which includes a cardiac surgeon experienced in mitral valve surgery and a cardiologist experienced in mitral valve disease

Existing comorbidities wouldn’t preclude the expected benefit from reduction of the mitral regurgitation.

Exclusions:

  • Patients who can’t tolerate procedural anticoagulation or post-procedural antiplatelet regimen
  • Active endocarditis of the mitral valve
  • Rheumatic mitral valve disease
  • Evidence of intracardiac, inferior vena cava or femoral venous thrombus
  • The individual is an appropriate candidate for the standard, open surgical approach but has refused
  • Transcatheter mitral valve annulus reshaping devices are under clinical trials
  • Non-FDA approved systems or approaches including:
    • Permavalve™ system
    • Transseptal and transapical approach

33961-33969

Not covered:
33999**

**Not otherwise classified procedure used to report non-arterial approach

Basic benefit and medical policy

Transcatheter aortic valve replacement

Transcatheter aortic valve replacement performed with an FDA-approved transcatheter heart valve system, performed via an approach consistent with the device’s FDA-approved labeling, may be indicated for patients with aortic stenosis.

Inclusions:
Transcatheter aortic valve replacement with a device approved by the FDA and performed via an approach consistent with the device’s FDA-approved labeling is established for patients with aortic stenosis when all the following conditions are present:

  • One of the following:
    • Severe aortic stenosis with a calcified aortic annulus
    • Failed (stenosed, insufficient or combined) of a surgical bioprosthetic aortic valve
  • New York Heart Association heart failure Class II, III or IV symptoms
  • Left ventricular ejection fraction greater than 20 percent
  • One of the following:
    • Patient isn’t an operable candidate for open surgery, as judged by at least two cardiovascular specialists including a cardiac surgeon.
    • Patient is an operable candidate but is at high risk for open surgery (i.e., Society of Thoracic Surgeons operative risk score ≥ 8 percent or at a ≥ 15 percent risk of mortality at 30 days).
    • Patient is at intermediate or greater surgical risk for open aortic valve replacement (only when used in concordance with FDA
      regulations for Sapien XT transcatheter heart valve; see below)

Edwards SAPIEN XT transcatheter heart valve:

  1. Severe aortic stenosis with a calcified aortic annulus and one or more of the following:
    • An aortic valve area of ≤ 1.0 cm² or aortic valve area index ≤ 0.6 cm2/m2
    • A mean aortic valve gradient ≥ 40 mmHg
    • A peak aortic-jet velocity ≥ 4.0 m/sec
    • Native anatomy appropriate for the 23, 26, or 29 mm valve system (between 18 and 28 mm)
  2. New York Heart Association heart failure Class II, III or IV symptoms
  3. Patient isn’t a candidate for open surgery, as judged by a heart team, including a cardiac surgeon, or to be at high or greater risk for open surgical therapy (i.e., Society of Thoracic Surgeons operative risk score ≥ 8 percent or at a ≥ 15 percent risk of mortality at 30 days).
  4. Patient is at intermediate surgical risk for open aortic valve replacement (i.e., predicted risk of surgical mortality ≥ 3 percent at 30 days based on the Society of Thoracic Surgeons Risk Score, or STS, and other clinical comorbidities unmeasured by the STS risk calculator)

Medtronic CoreValve™ (Evolut) system:

  1. Severe aortic stenosis with a calcified aortic annulus and one or more of the following:
    • An aortic valve area of ≤ 1.0 cm² or aortic valve area index ≤ 0.6 cm2/m2
    • A mean aortic valve gradient ≥ 40 mmHg
    • A peak aortic-jet velocity ≥ 4.0 m/sec
    • Native aortic annulus diameters between 23 and 31 mm
  2. New York Heart Association heart failure Class II, III or IV symptoms
  3. Patient is judged by a heart team, including a cardiac surgeon, to be at extreme risk or inoperable for open surgical therapy (predicted risk of operative mortality and/or serious irreversible morbidity ≥ 15 percent at 30 days).

Exclusions:
Transcatheter aortic valve replacement is considered experimental for all other indications, including but not limited to:

  • The individual is an appropriate candidate for the standard, open surgical approach but has refused.
  • Hypersensitivity or contraindication to an anticoagulation/antiplatelet regimen.
  • Presence of active bacterial endocarditis or other active infections.
  • Non-FDA approved systems or approaches including:
    • Lotus, Portico and JenaValve systems
    • Transcaval approach

Relative contraindications:
In some cases, the benefits of transcatheter aortic valve implantation may exceed potential risks. In such instances, the cardiologist should provide an attestation indicating that a relative contraindication(s) exists and that the patient fully understands all risks. While the items below are not absolute exclusions, the safety and effectiveness of transcatheter aortic valve implantation have not been evaluated in patients with the following characteristics or co-morbidities:

  • Patients without aortic stenosis
  • Untreated, clinically significant coronary artery disease requiring revascularization
  • Cardiogenic shock manifested by low cardiac output, vasopressor dependence or mechanical hemodynamic support
  • Transarterial access not able to accommodate an 18-Fr sheath
  • Sinus of valsalva anatomy that would prevent adequate coronary perfusion
  • End-stage renal disease requiring chronic dialysis or creatinine clearance <20 cc/min
  • Symptomatic carotid or vertebral artery disease
  • Safety, effectiveness and durability haven’t been established for valve-in-valve procedures.
  • Non-calcified aortic annulus
  • Severe ventricular dysfunction with ejection fraction < 20 percent
  • Congenital unicuspid or congenital bicuspid aortic valve
  • Mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant aortic regurgitation > 3+)
  • Prosthetic ring in any position
  • Severe mitral annular calcification, severe mitral insufficiency, moderate to severe mitral or tricuspid regurgitation, or Gorlin syndrome
  • Moderate to severe mitral stenosis
  • Blood dyscrasias defined as leukopenia, acute anemia (Hb < 9 g/dL), thrombocytopenia, history of bleeding diathesis or coagulopathy, or hypercoagulable states
  • Hypertrophic cardiomyopathy with or without obstruction
  • Echocardiographic evidence of intracardiac mass, thrombus or vegetation
  • Excessive calcification of vessel at access site
  • Bulky calcified aortic valve leaflets in close proximity to coronary ostia
  • The safety and effectiveness of the Medtronic CoreValve™ system have not been evaluated in the pediatric population.

90739

Basic benefit and medical policy

HEPLISAV-B — Hepatitis B vaccine (recombinant), adjuvated

Effective Jan. 8, 2018, the HEPLISAV-B vaccine is approved for the FDA indication for active immunization against infection caused by all known subtypes of hepatitis B virus. HEPLISAV-B is approved for use in adults 18 and older.

URMBT is excluded from this policy change.

J3490

Basic benefit and medical policy

Eskata (hydrogen peroxide)

Eskata (hydrogen peroxide) is considered cosmetic, effective June 14, 2018. This service isn’t a covered benefit.

The NDC is 71180-0001-12.

J3590

Basic benefit and medical policy

Fecal microbiota material

We aren’t allowing payment for fecal microbiota material under J3590 because codes aren’t yet available to reflect material, and material isn’t separately reimbursable.

Q2040

Basic benefit and medical policy

Kymriah (tisagenlecleucel)

Effective May 1, 2018, Kymriah (tisagenlecleucel) is payable for the following additional FDA indication: Adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma, known as DLBCL, not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma.

Kymriah (tisagenlecleucel) is a CD19-directed genetically modified autologous T-cell immunotherapy.

Limitation of use: Kymriah (tisagenlecleucel) isn’t indicated for treatment of patients with primary central nervous system lymphoma.

Dosing of Kymriah (tisagenlecleucel) is based on the number of chimeric antigen receptor (CAR)-positive viable T cells.

Pediatric and young adult B-cell (up to 25 years of age):

  • For patients 50 kg or less, administer 0.2 to 5.0 x 106 CAR-positive viable T cells per kg body weight intravenously.
  • For patients above 50 kg, administer 0.1 to 2.5 x 108 total CAR-positive viable T cells (non-weight based) intravenously.

Adult relapsed or refractory diffuse large B-cell lymphoma:

  • Administer 0.6 to 6.0 x 108 CAR-positive viable T cells intravenously.
EXPERIMENTAL PROCEDURES

0054T, 0055T, 0058T, 0071T, 0072T,
0075T, 0076T, 0085T, 0098T, 0101T,
0102T, 0106T- 0111T, 0126T, 0159T,
0163T- 0165T, 0174T, 0175T,
0188T-0190T, 0195T, 0196T, 0198T, 0200T-0202T, 0205T-0212T,
0215T-0222T, 0228T-0232T,
0235T-0238T, 0253T, 0254T,
0263T-0274T, 0278T, 0290T,

0312T-0317T, 0329T-0333T, 0335T,
0337T-0339T, 0341T, 0342T,
0346T-0358T, 0375T-0391T,
0394T-0398T, 0400T, 0401T,
0403T-0418T, 0421T-0437T, 0439T, 0440T-0448T, 0451T-0463T,
0465T-0468T, 0470T-0473T,

0475T-0500T, 0505T-0508T

Basic benefit and medical policy

CPT Category III codes — non-covered services

The procedures, services and tests in this policy have been determined to be experimental. They’re not a covered benefit for all contracts that exclude reimbursement for experimental services, effective Nov. 1, 2018.

Inclusions:

  1. Governmental approval of a service will be considered in determining whether a service is experimental. The fact that a service has received governmental approval doesn’t necessarily mean that it’s a proven benefit or appropriate or effective treatment for a particular diagnosis or for a particular condition.
  2. In determining whether there is rigorous scientific evidence to determine if a service is or isn’t experimental, we require that all the following five criteria be met:
    • A service that is a medical device, drug or biological product must have received final approval from the appropriate government regulatory bodies; such as the FDA. Any other approval granted as an interim step in the FDA regulatory process (e.g., an investigational device exemption or an investigational new drug exemption) isn’t sufficient.
    • Published, peer-reviewed medical literature must provide conclusive evidence that the service has a definite, positive effect on health outcomes. The evidence must include reports of well-designed investigations that have been reproduced by nonaffiliated, authoritative sources with measurable results, backed up by the positive endorsements of national medical bodies or panels regarding scientific efficacy and rationale.
    • Published, peer-reviewed medical literature must provide demonstrated evidence that, over time, the service leads to improvement in health outcomes (e.g., the beneficial effects of the service outweigh any harmful effects).
    • Published, peer-reviewed medical literature must provide proof that the service is at least as effective in improving health outcomes as established services or technologies or is usable in appropriate clinical contexts in which an established service or technology is not employable.
    • Published, peer-reviewed medical literature must provide proof that improvement in health outcomes is possible in standard conditions of medical practice, outside of clinical investigatory settings.
  3. The Federal Employee Health Benefit Program requires that procedures, devices or laboratory tests approved by the FDA may not be considered investigational and therefore these procedures, devices or laboratory tests may be assessed only on the basis of their medical necessity.

38999**

Basic benefit and medical policy

Lymphedema — surgical treatments

Lymphatic physiologic microsurgery to treat lymphedema (including, but not limited to, lymphatico-lymphatic bypass, lymphovenous bypass, lymphaticovenous anastomosis, autologous lymph node transplantation and vascularized lymph node transfer) in individuals who have been treated for breast cancer is experimental. It hasn’t been scientifically demonstrated to improve patient clinical outcomes.

Lymphatic physiologic microsurgery performed during nodal dissection or breast reconstruction to prevent lymphedema (including, but not limited to, the lymphatic microsurgical preventing healing approach) in individuals who are being treated for breast cancer is experimental. It hasn’t been scientifically demonstrated to improve patients’ clinical outcomes.

This policy is effective Nov. 1, 2018.

Payment policy
**Unlisted procedure code used to report this service.

Exclusions:
Liposuction in patients with more advanced lymphedema after fat deposition and tissue fibrosis

64505, 64999

Basic benefit and medical policy

Sphenopalatine ganglion block for headache

Sphenopalatine ganglion blocks are considered experimental for all indications, including, but not limited to, the treatment of migraines and non-migraine headaches. This policy is effective Nov. 1, 2018.

GROUP BENEFIT CHANGES

Kelly Services Inc.  

Kelly Services, group number 75100, added “Inc.” to its name.

Group number: 75100
Alpha prefix: PPO (KSP)
Platform: NASCO

Plans offered:
PPO medical/surgical
Prescription drug

CDH — HSA

The Auto Club Group

The Auto Club Group, group number 72695, is adding a health savings account plan.

Mahle Behr USA Inc. 

Mahle Behr USA Inc., group number 71775, is joining Blue Cross Blue Shield of Michigan, effective Jan. 1, 2019.

Group number: 71775
Alpha prefixes: PPO (MDA), CMM (ZFI)
Platform: NASCO Hybrid

Plans offered:
PPO, medical/surgical
Vision (VSP)
Prescription drugs
Hearing
CDH — Medical FSA and Dependent Care FSA through HEQ

Mahle Industries Incorporated

Mahle Industries Incorporated, group number 71774, is joining Blue Cross Blue Shield of Michigan, effective Jan. 1, 2019.

Group number: 71774
Alpha prefix: PPO (MDA) 
Platform: NASCO Hybrid

Plans offered:
PPO, medical/surgical
Vision (VSP)
Prescription drugs
Hearing
CDH — Medical FSA and Dependent Care FSA through HEQ

No portion of this publication may be copied without the express written permission of Blue Cross Blue Shield of Michigan, except that BCBSM participating health care providers may make copies for their personal use. In no event may any portion of this publication be copied or reprinted and used for commercial purposes by any party other than BCBSM.

*CPT codes, descriptions and two-digit numeric modifiers only are copyright 2017 American Medical Association. All rights reserved.